Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma

doi:10.3748/wjg.v26.i3.324

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8284)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

521

WORD

132

HTML

4138

Figures (1-3)

1001

Tables (1-2)

287

Sum=6079

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

774

Download

1431

Sum=2205

Jan 21, 2020 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jan 21, 2020; 26(3): 324-334
Published online Jan 21, 2020. doi: 10.3748/wjg.v26.i3.324

Full Size Figure Download Figure

Figure 2 Comparison of tumor response and survival in doxorubicin (doxorubicin-based transarterial chemoembolization) vs idarubicin (idarubicin-based transarterial chemoembolization) patients. A: Progression-free survival; B: Liver transplant-free survival; C: Objective response; D: Disease control rate. TACE: Transarterial chemoembolization; Dox-TACE: Doxorubicin-based transarterial chemoembolization; Ida-TACE: Idarubicin-based transarterial chemoembolization.

Citation: Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T. Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 324-334
URL: https://www.wjgnet.com/1007-9327/full/v26/i3/324.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i3.324